On the other hand, blend therapy brought on 99% regression of
intestinal tumors. It has been advised that STAT 3 inhibitors show synergistic interactions with dasatinib in HNSCC 42. As a result, in order to attain a far better therapeutic efficacy, targeting a number of pathways concurrently is warranted. We have reported that dietary agent curcumin enhances the efficacy of Folfox and the pan erbB inhibitor ERRP in colon cancer cells in vitro.
